Boehringer Ingelheim is a leading research-driven biopharmaceutical company committed to advancing human and animal health. As one of the industrys top global investors in R&D, we focus on developing innovative therapies that address areas of high unmet medical need, improving and extending lives worldwide.
BI
Boehringer Ingelheim
Company · Germany · EU Transparency Register 289777818743-24
2
positions filed
in the 326 files tracked
2
legislative files
of 326 tracked
1
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 326 consultation files tracked so far (29,503 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 925 companies & groups on this site, they rank #377 by legislative files engaged — a count of participation, not a measure of influence.
2
declared lobbying FTE
self-declared
€2M+
declared costs / yr (floor)
4
EP accreditations
as declared to the register
2015
in the register since
Declares membership of
- The following is a list of the main associations of which Boehringer is an active member:
- European Federation of Pharmaceutical Industries and Associations (EFPIA)
- AnimalhealthEurope →
- International Pharmaceutical Aerosol Consortium (IPAC)
- European Animal Research Association (EARA)
- Verband der Chemischen Industrie (VCI)
- EU-ASEAN Business Council
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026).
- Register category
- Companies & groups
- Head office
- Ingelheim, Germany
- EU office
- Brussels
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Boehringer in PolicySpeak: request access →
Work at Boehringer Ingelheim? so we know who speaks for it.
Their record over time
Boehringer Ingelheim filed 2 positions between 11 Jun 2025 and 19 May 2026, across 2 of the 326 legislative files tracked here, attaching a full position paper 1 time.
2025 · 1 filed2026 · 1 filed
What they argued
CVD remains the leading cause of mortality in the EU, yet a substantial share of risk factors and underlying conditions remain undetected. Early CVD detection efforts must better reflect the interconnected nature of cardiovascular, renal and metabolic (CRM) conditions, which frequently co-exist, amplify one another, and significantly increase the risk of adverse outcomes.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers — not evidence of coordination, and we do not suggest any.
- IDEE ECONOMICHE www.idee-economiche.it · 2 files in common
- MedTech Europe · 2 files in common
- EFPIA · 2 files in common
- Deutsche Sozialversicherung Europavertretung (DSV) · 2 files in common
- Helmholtz Association of German Research Centres · 2 files in common
Showing 5 of 19.
Is this your organization?
Everything on this page comes from Boehringer Ingelheim’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.